ArticleFrontiers in oncology2025
Successful rescue of PD-1 inhibitor-induced TEN by vincristine combination therapy: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toxic Epidermal Necrolysis in a Patient with Hepatocellular Carcinoma Receiving Pembrolizumab Plus Regorafenib: A Case Report.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the growing use of immune checkpoint inhibitors (ICIs) in the management of various solid malignancies, immune-related adverse events (irAEs) are increasingly recognized. Toxic epidermal necrolysis (TEN), though rare, represents a severe and potentially fatal cutaneous irAE with a high mortality rate. Owing to its low incidence and limited clinical data, a standardized treatment approach for ICI-induced TEN has not been established. We present a patient who developed TEN following the administration of a programmed cell death-1 inhibitor. The patient was successfully managed with a combination of vincristine, intravenous immunoglobulin, and glucocorticoids at the Department of Oncology, Guangzhou Chest Hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.